WELCOME ALL TO YOUR No 2 RALLY!!! Investing is a delicate balancing act and often you get all wet- But there is beauty in the attempt...
Moderna (NASDAQ:MRNA) declined to transfer the core intellectual property (IP) of its mRNA COVID vaccine to China, causing a fallout in discussions on the sale of vaccine there,Financial Timesreportedon Oct. 1 citing people familiar withthe matter. Moderna refused to hand over the IP vaccine due to commercial and safety concerns, said two people involved in discussions which took place between 2020 and 2021, the report added.
Aug 29- stk was $3.80 Calithera Biosciences (NASDAQ:CALA) is trading~8% higherafter HC Wainwright upgrades rating to Buy to Neutral, with an $8 price target. HC Wainwright analyst Swayampakula Ramakant believes the company has sufficient cash to fund operations into Q2 of 2023. The companyhad cash and cash equivalents of $41.8M at June 30. Calithera has two ongoing clinical development programs that are expected to provide data updates in Q1 of 2023, Ramakanth tells investors in a research note. If positive, both drugs could be evaluated in registrational studies to achieve accelerated FDA approval, says the analyst. He estimates Calithera to achieve risk-adjusted revenues of $111M by 2030. Today- CALA Calithera Biosciences, Inc. $2.94-0.02(-0.68%)11:49 AM 09/30/22 NASDAQ |$USD |Pre-Market:$3.62+0.68(+23.13%)4:39 AM
STOCK OF THE DAY - LEVI- $14.75 Bank of America pounded the table on its bullish view of Levi Strauss & Co. (NYSE:LEVI) just ahead of the apparel company's earnings report on October 6. Crucially for the stock, BofA thinks market concerns regarding a structural shift out of denim are overblown. Analyst Christopher Nardone and team view LEVI as a best in class brand with a compelling strategy around the shift to direct to consumer. They also see a solid runway for LEVI to expand market share in both denim and non-denim categories. On valuation, BofA noted that the stock is trading at an attractive multiple of 6.7X the firm's 2023 EV/EBITDA estimate, which in itself is 9% below the consensus mark. BofA has a Buy rating on LEVI and price objective of $20 to rep more than 40% upside potential for shares.
2nd Stock Of The day- FLUOR- 1 year up 55% who else can say that! Van and I have been on this name since $19. It is a great IRA stock. And friendly as heck with China! Fluor secures two projects of $2B for BASF Zhanjiang Verbund site project in China Oct. 03, 2022 7:36 AM ET Fluor Corporation (FLR),FLRAP Fluor (NYSE:FLR) on Monday has secured two reimbursable engineering, procurement and construction management contracts by BASF for the ethylene oxide/ethylene glycol and infrastructure, offsites and utilities packages as part of the company’s new Verbund program in Zhanjiang, Guangdong province, China. The contract value to Fluor is more than $2B and was booked in the third quarter of 2022. The project will be led by Fluor’s Shanghai, China, office.
No 2 Buy Recommendation- Dutch Brothers- - Buy $31.50 area<------------ -> BROS Dutch Bros Inc. $31.15-1.27(-3.92%)12:00 PM 09/30/22 NYSE |$USD |Pre-Market:$31.75+0.60(+1.93%)4:46 AM
I've been following LIDAR space for as long as there has been one. INVZ stands out.- Innoviz, Luminar rated at ‘Buy’, Velodyne at ‘Sell’ as JP Morgan assesses LiDAR players Sep. 20, 2022 11:27 AM ETInnoviz Technologies Ltd. (INVZ) JP Morgan analyst Samik Chatterjee told clients that while opportunity is likely to abound in LiDAR technologies in coming years, stockpicking remains paramount in the sector. “We believe the debate around value-add of a LiDAR in asensing suite has been long settled, with decisions to exclude LiDARs largely a cost-based decision rather than performance,” he wrote. “However, debates remain rife in relation to the winning technology approach in LiDAR, the differentiation between players and the recipe for success as automakers pursue a multi-pronged strategy of preparing some vehicle platforms for L2 functionalities while some OEMs look to leap frog to L3+ with some other developments.” In terms of top picks, Chatterjee selected Innoviz (NASDAQ:INVZ) and Luminar (NASDAQ:LAZR) as the best options for investors at present. Meanwhile, Cepton (NASDAQ:CPTN) and Velodyne Lidar (NASDAQ:VLDR) were rated at Hold and Sell-equivalent ratings, respectively. He explained that Innoviz (INVZ) is particularly underappreciated as its industry-leading order book and “compelling margins” add to its observable ramp in revenue. “We expect the combination of numerous wins, large volume wins, balance of LiDAR costs and performance and ability to support highway autonomy at high speeds to position Innoviz to ramp revenues well into the end of the decade, while cost discipline should drive profitability,” Chatterjee wrote.